Planet Briefing

First published · Last updated

The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study

A multicenter retrospective journal article evaluating the CALLY Index in patients with unresectable or recurrent gastric cancer treated with nivolumab.

An NIAID clinical trial admissions coordinator collects information from a volunteer to create a medical record. Credit: NIAID
Illustrative image: An NIAID clinical trial admissions coordinator collects information from a volunteer to create a medical record. Credit: NIAID — NIAID/Wikimedia Commons, CC BY 2.0

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
2/10
Geographic reach
2/10
Global importance
3/10
Impact magnitude
3/10
Positivity
5/10
Urgency
2/10

Why it matters

The study concerns clinical assessment tools for gastric cancer patients receiving nivolumab.

Sources

Report an issue